FIGURE 5.

ENKTL patients who showed complete remission (CR) or a different response (non‐CR) after two rounds of treatment did not differ significantly in post‐treatment expression of A, PD‐1 on CD4+ T cells, B, PD‐L1 on CD4+ T cells, or C, PD‐L1 on CD8+ T cells in peripheral blood. D‐E, The CR and non‐CR response groups showed similar pretreatment levels of PD‐L1 mRNA. F, In the CR group, two rounds of treatment reduced the levels of PD‐L1 mRNA to the levels in controls. G‐H, The CR group showed statistically lower pretreatment levels of sPD‐L1 than the non‐CR group. I, In the CR group, two rounds of treatment reduced the levels of sPD‐L1 to the levels in controls. *P < .05, **P < .01, ***P < .001, ****P < .0001. ENKTL, extranodal natural killer/T‐cell lymphoma; NS, not significant